Abstract
The researchers will assess the safety, tolerability, dosing effect, and early signals of efficacy of intra-arterially delivered autologous (from self) adipose (fat) tissue-derived mesenchymal stem/stromal cells (MSC) in patients with progressive diabetic kidney disease (DKD).
Mayo Clinic in Rochester, Rochester, Minnesota, USA
ClinicalTrials.gov Identifier: NCT03840343
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Weiss, J.N. (2022). Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease. In: Stem Cell Surgery Trials in Heart Failure and Diabetes. Springer, Cham. https://doi.org/10.1007/978-3-030-78010-4_20
Download citation
DOI: https://doi.org/10.1007/978-3-030-78010-4_20
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-78009-8
Online ISBN: 978-3-030-78010-4
eBook Packages: MedicineMedicine (R0)